Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) and Savara (NASDAQ:SVRA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.
Earnings and Valuation
This table compares Ernexa Therapeutics and Savara”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ernexa Therapeutics | $580,000.00 | 15.08 | -$44.54 million | ($8.31) | -0.14 |
| Savara | N/A | N/A | -$95.88 million | ($0.50) | -7.04 |
Analyst Recommendations
This is a summary of current recommendations and price targets for Ernexa Therapeutics and Savara, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ernexa Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Savara | 0 | 1 | 5 | 0 | 2.83 |
Savara has a consensus price target of $7.50, indicating a potential upside of 113.07%. Given Savara’s stronger consensus rating and higher probable upside, analysts clearly believe Savara is more favorable than Ernexa Therapeutics.
Institutional & Insider Ownership
70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 4.5% of Ernexa Therapeutics shares are owned by insiders. Comparatively, 5.1% of Savara shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Ernexa Therapeutics and Savara’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ernexa Therapeutics | -7,652.75% | N/A | -682.08% |
| Savara | N/A | -69.05% | -54.84% |
Volatility and Risk
Ernexa Therapeutics has a beta of 5.66, suggesting that its share price is 466% more volatile than the S&P 500. Comparatively, Savara has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.
Summary
Savara beats Ernexa Therapeutics on 8 of the 13 factors compared between the two stocks.
About Ernexa Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
About Savara
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Receive News & Ratings for Ernexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ernexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
